RHL Group’s Beam Therapeutics BEAM Stock Holding History

RHL Group’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$24	Buy	+1	New	+$28	﹤0.01%	356

Other funds holding BEAM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

RHL Group's BEAM Position: Q3 2026 in Review

RHL Group opened a new position in Beam Therapeutics (BEAM) in Q3 2026: 1 share worth $24. The stake represents ﹤0.01% of the portfolio and ranks #356 among its holdings.

85 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

RHL Group held 1 share of Beam Therapeutics worth $24 as of Q3 2026.
Beam Therapeutics was a new RHL Group position in Q3 2026.
Beam Therapeutics made up ﹤0.01% of RHL Group's portfolio in Q3 2026, its #356 holding.
85 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on RHL Group's 13F filing for Q3 2026, filed 4 Nov 2026.